α-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 5, 2015, Pages H926-H934

  De Queiroz, Thyago M ^a,d   Xia, Huijing ^a,c   Filipeanu, Catalin M ^a,c   Braga, Valdir A ^d   Lazartigues, Eric ^a,b,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Antioxidant; Deoxycorticosterone acetate salt hypertension; Metalloprotease 17; Type 2 angiotensin converting enzyme

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; DEOXYCORTICOSTERONE ACETATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; THIOCTIC ACID; UNCLASSIFIED DRUG; ADAM17 PROTEIN, MOUSE; ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DYSAUTONOMIA; ENZYME ACTIVITY; EXPERIMENTAL HYPERTENSION; HYPOTHALAMUS; MALE; MOUSE; NEUROBLASTOMA CELL LINE; NONHUMAN; OXIDATIVE STRESS; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; GENETICS; HYPERTENSION; METABOLISM; NERVE CELL; TUMOR CELL LINE;

ADAM PROTEINS; ADAM17 PROTEIN; ANGIOTENSIN II; ANIMALS; ANTIOXIDANTS; BAROREFLEX; CELL LINE, TUMOR; HYPERTENSION; HYPOTHALAMUS; MALE; MICE; MICE, INBRED C57BL; NADPH OXIDASE; NEURONS; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; THIOCTIC ACID;

EID: 84940785354     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00259.2015     Document Type: Article

References (48)

1. Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 15: 2319-2335, 2009.
2. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37: 781-786, 2001.
3. Biewenga GP, Haenen GRMM, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 29: 315-331, 1997.
4. Botelho-Ono MS, Pina HV, Sousa KHF, Nunes FC, Medeiros IA, Braga VA. Acute superoxide scavenging restores depressed baroreflex sensitivity in renovascular hypertensive rats. Auton Neurosci 159: 38-44, 2011.
5. Braga VA. Dietary salt enhances angiotensin-II-induced superoxide formation in the rostral ventrolateral medulla. Auton Neurosci 155: 14-18, 2010.
6. Brill A, Chauhan AK, Canault M, Walsh MT, Bergmeier W, Wagner DD. Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion. Cardiovasc Res 84: 137-144, 2009.
7. Burmeister MA, Young CN, Braga VA, Butler SD, Sharma RV, Davisson RL. In vivo bioluminescence imaging reveals redox-regulated activator protein-1 activation in paraventricular nucleus of mice with renovascular hypertension. Hypertension 57: 289-297, 2011.
8. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular nadph oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 38: 606-611, 2001.
9. Chodavarapu H, Grobe N, Somineni HK, Salem ESB, Madhu M, Elased KM. Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLOS ONE 8: e62833, 2013.
10. Chow FL, Fernandez-Patron C. Many membrane proteins undergo ectodomain shedding by proteolytic cleavage. Does one sheddase do the job on all of these proteins? IUBMB Life 59: 44-47, 2007.
11. Chrissobolis S, Banfi B, Sobey CG, Faraci FM. Role of Nox isoforms in angiotensin II-induced oxidative stress and endothelial dysfunction in brain. J Appl Physiol 113: 184-191, 2012.
12. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A. The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol 91: 472-485, 2012.
13. Epelman S, Tang WHW, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the reninangiotensin- aldosterone system. J Am Coll Cardiol 52: 750-754, 2008.
14. Feng Y, Xia H, Cai Y, Halabi CM, Becker LK, Santos RAS, Speth RC, Sigmund CD, Lazartigues E. Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res 106: 373-382, 2010.
15. Feng Y, Yue X, Xia H, Bindom SM, Hickman PJ, Filipeanu CM, Wu G, Lazartigues E. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin ii-mediated pressor and drinking responses and is associated with angiotensin ii type 1 receptor downregulation. Circ Res 102: 729-736, 2008.
16. Ford BM, Eid AA, Gooz M, Barnes JL, Gorin YC, Abboud HE. ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice. Am J Physiol Renal Physiol 305: F323-F332, 2013.
17. Garwitz ET, Jones AW. Aldosterone infusion into the rat and dosedependent changes in blood pressure and arterial ionic transport. Hypertension 4: 374-381, 1982.
18. Gavras H, Brunner HR, Laragh JH, Vaughan ED, Koss M, Cote LJ, Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 36: 300-309, 1975.
19. Grobe JL, Buehrer BA, Hilzendeger AM, Liu X, Davis DR, Xu D, Sigmund CD. Angiotensinergic signaling in the brain mediates metabolic effects of deoxycorticosterone (DOCA)-salt in C57 mice. Hypertension 57: 600-607, 2011.
20. Hilzendeger AM, Cassell MD, Davis DR, Stauss HM, Mark AL, Grobe JL, Sigmund CD. Angiotensin type 1a receptors in the subfornical organ are required for deoxycorticosterone acetate-salt hypertension. Hypertension 61: 716-722, 2013.
21. Itaya Y, Suzuki H, Matsukawa S, Kondo K, Saruta T. Central reninangiotensin system and the pathogenesis of DOCA-salt hypertension in rats. Am J Physiol Heart Circ Physiol 251: H261-H268, 1986.
22. Kim HS, Kim HJ, Park KG, Kim YN, Kwon TK, Park JY, Lee KU, Kim JG, Lee IK. α-Lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-[kappa]B transcriptional activity. Exp Mol Med 39: 106-113, 2007.
23. Lai ZW, Hanchapola I, Steer DL, Smith AI. Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: determinants and constraints. Biochemistry 50: 5182-5194, 2011.
24. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, Eguchi S. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin ii type-1 receptor. J Biol Chem 280: 26592-26599, 2005.
25. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C. MMP-2 mediates angiotensin ii-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 57: 123-130, 2011.
26. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 26: e133-e137, 2006.
27. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803, 2006.
28. Pedersen KB, Sriramula S, Chhabra K, Xia H, Lazartigues E. Speciesspecific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays. Am J Physiol Regul Integr Comp Physiol 301: R1293-R1299, 2011.
29. Queiroz TM, Guimaraes DD, Mendes LG Jr, Braga VA. α-Lipoic acid reduces hypertension and increases baroreflex sensitivity in renovascular hypertensive rats. Molecules 17: 13357-13367, 2012.
30. Sanderson MP, Abbott CA, Tada H, Seno M, Dempsey PJ, Dunbar AJ. Hydrogen peroxide and endothelin-1 are novel activators of betacellulin ectodomain shedding. J Cell Biochem 99: 609-623, 2006.
31. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 1790: 1149-1160, 2009.
32. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 101: 1722-1728, 2000.
33. Soond SM, Everson B, Riches DWH, Murphy G. ERK-mediated phosphorylation of Thr735 in TNFα-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 118: 2371-2380, 2005.
34. Sriramula S, Cardinale JP, Lazartigues E, Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res 92: 401-408, 2011.
35. Takaoka M, Kobayashi Y, Yuba M, Ohkita M, Matsumura Y. Effects of α-lipoic acid on deoxycorticosterone acetate-salt-induced hypertension in rats. Eur J Pharmacol 424: 121-129, 2001.
36. Xia H, Feng Y, Obr TD, Hickman PJ, Lazartigues E. Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension 53: 210-216, 2009.
37. Xia H, Sriramula S, Chhabra K, Lazartigues E. Brain ACE2 shedding contributes to the development of neurogenic hypertension. Circ Res 113: 1087-1096, 2013.
38. Xia H, Suda S, Bindom S, Feng Y, Gurley SB, Seth D, Navar LG, Lazartigues E. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One 6: e22682, 2011.
39. Xiao L, Gao L, Lazartigues E, Zucker IH. Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure. Hypertension 58: 1057-1065, 2011.
40. Xu H, Fink GD, Galligan JJ. Nitric oxide-independent effects of tempol on sympathetic nerve activity and blood pressure in DOCA-salt rats. Am J Physiol Heart Circ Physiol 283: H885-H892, 2002.
41. Xu H, Fink GD, Galligan JJ. Tempol lowers blood pressure and sympathetic nerve activity but not vascular O2- in DOCA-salt rats. Hypertension 43: 329-334, 2004.
42. Xu P, Derynck R. Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell 37: 551-566, 2010.
43. Xu P, Sriramula S, Lazartigues E. ACE2/Ang-(1-7)/Mas pathway in the brain: the Axis of Good. Am J Physiol Regul Integr Comp Physiol 300: R804-R817, 2011.
44. Xue B, Beltz TG, Johnson RF, Guo F, Hay M, Johnson AK. PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone/NaCl-induced hypertension in mice. Am J Physiol Heart Circ Physiol 302: H733-H741, 2012.
45. Yemane H, Busauskas M, Burris SK, Knuepfer MM. Neurohumoral mechanisms in deoxycorticosterone acetate (DOCA)-salt hypertension in rats. Exp Physiol 95: 51-55, 2010.
46. Zeng SY, Chen X, Chen SR, Li Q, Wang YH, Zou J, Cao WW, Luo JN, Gao H, Liu PQ. Upregulation of Nox4 promotes angiotensin ii-induced epidermal growth factor receptor activation and subsequent cardiac hypertrophy by increasing ADAM17 expression. Can J Cardiol 29: 1310-1319, 2013.
47. Zhang Z, Oliver P, Lancaster JJR, Schwarzenberger PO, Joshi MS, Cork J, Kolls JK. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J 15: 303-305, 2000.
48. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 95: 210-216, 2004.